Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
22 hedge funds and large institutions have $143M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$38.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13.2M |
| 5 |
Citigroup
New York
|
+$6.63M |
Top Sellers
LBPH Hedge Fund Activity: Q1 2021 in Review
22 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q1 2021, worth a combined $143M.
Buyers outnumbered sellers: 22 funds opened new LBPH positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $38.5M.
- 22 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $143M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q1 2021.
- 22 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +22 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Cormorant Asset Management, an estimated $38.5M added.
Based on aggregated 13F filings for Q1 2021.